Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details 1)	3 Months Ended		6 Months Ended		1 Months Ended		3 Months Ended			6 Months Ended
	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Feb. 29, 2012 Samsung Biosimilar Agreement [Member] USD ($)	Feb. 29, 2012 Samsung Biosimilar Agreement [Member] KRW	Jun. 30, 2014 Samsung Biosimilar Agreement [Member] USD ($)	Dec. 31, 2013 Samsung Biosimilar Agreement [Member] USD ($)	Jun. 30, 2013 Samsung Biosimilar Agreement [Member] USD ($)	Jun. 30, 2014 Samsung Biosimilar Agreement [Member] USD ($)	Jun. 30, 2013 Samsung Biosimilar Agreement [Member] USD ($)	Jun. 30, 2014 Samsung Biosimilar Agreement [Member] KRW	Dec. 31, 2013 Samsung Biosimilar Agreement [Member] KRW
Schedule of Equity Method Investments [Line Items]
Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals					$ 250,000,000	280,500,000,000
Variable interest entity, qualitative or quantitative information, ownership percentage					85.00%	85.00%
Contribution from Biogen Idec to develop, manufacture and market biosimilar pharmaceuticals					45,000,000	49,500,000,000	14,600,000	23,900,000		14,600,000		15,600,000,000	25,200,000,000
Percentage of stake in entity minimum					15.00%	15.00%	12.00%			12.00%
Percentage of stake in entity maximum					49.90%	49.90%
Recognized loss	(1,933,000)	(2,289,000)	(9,538,000)	(6,100,000)			(1,900,000)		(2,300,000)	(9,500,000)	(6,100,000)
Revenue related to technical development and technology transfer services	61,864,000	48,770,000	151,965,000	103,481,000			12,300,000		7,400,000	36,500,000	14,200,000
Research and development	447,273,000	327,463,000	976,157,000	611,803,000				36,000,000
Additional milestone payment								$ 85,000,000
Expected profit share with Samsung Bioepis								50.00%